Genetic alterations and biological pathways in human bladder cancer pathogenesis

Urologic Oncology

Volumn 5, Issue 5, 2000, Pages 191-203

  Reznikoff, Catherine A ^a   Sarkar, Somdatta ^a   Jülicher, Knut P ^a   Burger, Melissa S ^a   Puthenveettil, Jairaj A ^a   Jarrard, David F ^a   Newton, Michael A ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

Author keywords

Biological pathways; Bladder cancer; Genetics; Pathogenesis models

Indexed keywords

BLADDER CANCER; CHROMOSOME 9Q; GENE MUTATION; HUMAN; MALIGNANT TRANSFORMATION; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SQUAMOUS CELL CARCINOMA; TRANSITIONAL CELL CARCINOMA;

EID: 0033829167     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1078-1439(00)00079-X     Document Type: Review

References (131)

1. Jones P.A., Droller M.J. Pathways of development and progression in bladder cancer. new correlations between clinical observations and molecular mechanisms Semin Urol. 4:1993;177-192.
2. Kroft S.H., Oyasu R. Biology of disease - urinary bladder cancer. mechanisms of development and progression Lab Invest. 71:1994;158-174.
3. Knowles M.A. Molecular genetics of bladder cancer. Br J Urol. 75:1995;57-66.
4. Cordon-Cardo C., Sheinfeld J., Dalbagni G. Genetic studies and molecular markers of bladder cancer (Review). Semin Surg Oncol. 13:1997;319-327.
5. Cancer Facts and Figures. American Cancer Society, 1998.
6. Kantor A.F., Hartge P., Hoover R.N.et al. Epidemiological characteristics of squamous cell carcinoma and adenocarcinoma of the bladder. Cancer Res. 48:1988;3853-3855.
7. Zingg EJ, Wallace DMA. Clinical practice in urology. In: Chisholm GD, series editor. Bladder Cancer. Berlin, Heidelberg: Springer-Verlag, 1985.
8. Lamm DL, Lamm DA. Superficial Bladder Cancer. Highlights of the ASCO 32nd Annual Meeting, Philadelphia, PA, May 1996.
9. Brinkley W.M., Torti F.M. Systemic chemotherapy of transitional cell carcinoma of the urothelium. Semin Surg Oncol. 13:1997;365-375.
10. McCaffrey J.A., Bajorin D.F., Scher H.I.et al. Combined-modality therapy for bladder cancer. Oncol. 11:1997;18-26.
11. Sidransky D., Frost P., VonEschenbach A.et al. Clonal origin of bladder cancer. N Engl J Med. 326:1992;737-740.
12. Chern H.D., Becich M.J., Persad R.A.et al. Clonal analysis of human recurrent superficial bladder cancer by immunohistochemistry of p53 and retinoblastoma proteins. J Urol. 156:1996;1846-1849.
13. Tsai Y.C., Simoneau A.R., Spruck C.H. III et al. Mosaicism in human epithelium. macroscopic monoclonal patches cover the urothelium J Urol. 153:1995;1697-1700.
14. Minervini R., Felipetto R., Vigano L.et al. Recurrences and progression of superficial bladder cancer following long-term intravesical prophylactic therapy with mitomycin CB 48-month follow-up. Urol Inter. 56:1996;234-237.
15. Herr H.W. Natural history of superficial bladder tumors B 10- to 20-year follow-up of treated patients. World J Urol. 15:1997;84-88.
16. Cookson M.S., Herr H.W., Zhang Z.F.et al. The treated natural history of high risk superficial bladder cancer. 15-year outcome J Urol. 158:1997;62-67.
17. Zhang G.K., Uke E.T., Sharer W.C.et al. Reassessment of conservative management for stage T1N0M0 transitional cell carcinoma of the bladder. J Urol. 155:1996;1907-1909.
18. Spruck C.H. III, Ohneseit P.F., Gonzalez-Zulueta M.et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res. 54:1994;784-788.
19. Reznikoff C.A., Belair C.D., Yeager T.R.et al. A molecular genetic model of human bladder cancer pathogenesis. Semin Oncol. 23:1996;571-584.
20. Sandberg A.A., Berger C.S. Review of chromosome studies in urological tumors. II. Cytogenetics and molecular genetics of bladder cancer. J Urol. 151:1994;545-560.
21. Gibas Z., Gibas L. Cytogenetics of bladder cancer. Cancer Genet Cytogenet. 95:1997;108-115.
22. Kallioniemi A., Kallioniemi O.-P., Citro G.et al. Identification of gains and losses of DNA sequences in primary bladder cancer by comparative genomic hybridization. Genes Chromosomes Cancer. 12:1995;213-219.
23. Richter J., Jiang F., Görög J.-P.et al. Marked genetic differences between stage pTa and stage pT1 papillary bladder cancer detected by comparative genomic hybridization. Cancer Res. 57:1997;2860-2864.
24. Hovey R.M., Chu L., Balazs M.et al. Genetic alterations in primary bladder cancers and their metastases. Cancer Res. 58:1998;3555-3560.
25. Habuchi T., Ogawa O., Kakehi Y.et al. Accumulated allelic losses in the development of invasive urothelial cancer. Int J Cancer. 53:1993;579-584.
26. Knowles M.A., Elder P.A., Williamson M.et al. Allelotype of human bladder cancer. Cancer Res. 54:1994;531-538.
27. Presti J.C. Jr., Reuter V.E., Galan T.et al. Molecular genetic alterations in superficial and locally advanced human bladder cancer. Cancer Res. 51:1991;5405-5409.
28. Li M., Zhang Z.F., Reuter V.E.et al. Chromosome 3 allelic losses and microsatellite alterations in transitional cell carcinoma of the urinary bladder. Am J Pathol. 149:1996;229-235.
29. Yeager T.R., DeVries S., Jarrard D.F.et al. Overcoming cellular senescence in human cancer pathogenesis. Genes Dev. 12:1998;163-174.
30. Bell S.M., Zuo J., Myers R.M.et al. Fluorescence in situ hybridization deletion mapping at 4p16.3 in bladder cancer cell lines refines the localization of the critical interval to 30 kb. Genes Chromosomes Cancer. 17:1996;108-117.
31. Waldman F.M., Carroll P.R., Kerschmann R.et al. Centromeric copy number of chromosome 7 is strongly correlated with tumor grade and labeling index in human bladder cancer. Cancer Res. 51:1991;3807-3813.
32. Takle L.A., Knowles M.A. Deletion mapping implicates two tumor suppressor genes on chromosomes 8p in the development of bladder cancer. Oncogene. 12:1996;1083-1087.
33. Wagner U., Bubendorf L., Gasser T.C.et al. Chromosome 8p deletions are associated with invasive tumor growth in urinary bladder cancer. Am J Path. 151:1997;753-759.
34. Sauter G., Carroll P., Moch H.et al. c-myc copy number gains in bladder cancer detected by fluorescence in situ hybridization. Am J Path. 146:1995;1131-1139.
35. Ruppert J.M., Tokino K., Sidransky D. Evidence for two bladder cancer suppressor loci on human chromosome 9. Cancer Res. 53:1993;593-595.
36. Cairns P., Shaw M.E., Knowles M.A. Preliminary mapping of the deleted region of chromosome 9 in bladder cancer. Cancer Res. 53:1993;1230-1232.
37. Miyao N., Tsai Y.C., Lerner S.P. Role of chromosome 9 in human bladder cancer. Cancer Res. 53:1993;4066-4070.
38. Orlow I., Lianes P., Lacombe L.et al. Chromosome 9 allelic losses and microsatellite alterations in human bladder tumors. Cancer Res. 54:1994;2848-2851.
39. Habuchi T., Devlin J., Elder P.A., Knowles M.A. Detailed deletion mapping of chromosome 9q in bladder cancer. evidence for two tumour suppressor loci Oncogene. 11:1995;1671-1674.
40. Simoneau A.R., Spruck C.H., Gonzalez-Zulueta M.et al. Evidence for two tumor suppresor loci associated with proximal chromosome 9p to q and distal chromosome 9q in bladder cancer and the initial screening for GAS1 and PTC mutations. Cancer Res. 56:1996;5039-5043.
41. Habuchi T., Yoshida O., Knowles M.A. A novel candidate tumour suppressor locus at 9q32-q33 in bladder cancer. localization of the candidate region within a single 840 kb YAC Hum Mol Genet. 6:1997;913-919.
42. Stadler W.M., Sherman J., Bohlander S.K.et al. Homozygous deletions within chromosomal bands 9p21-22 in bladder cancer. Cancer Res. 54:1994;2060-2063.
43. Spruck C.H. III, Gonzalez-Zulueta M., Shibata A.et al. p16 gene in uncultured tumours. Scientific Correspondence. Nature. 370:1994;183-184.
44. Cairns P., Mao L., Merlo A.et al. Rates of p16 (MTS1) mutations in primary tumors with 9p Loss. Technical Comments. Science. 265:1994;415-416.
45. Cairns P., Polascik T.J., Eby Y.et al. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet. 11:1995;210-212.
46. Williamson M.P., Elder P.A., Shaw M.E.et al. p16 (CDKN2) is a major deletion target at 9p21 in bladder cancer. Hum Mol Genet. 4:1995;1569-1577.
47. Balázs M., Carroll P., Kerschmann R.et al. Frequent homozygous deletion of cyclin-dependent kinase inhibitor 2 (MTSI, p16) in superficial bladder cancer detected by fluorescence in situ hybridization. Genes Chromosomes Cancer. 19:1997;84-89.
48. Okajima E., Fukuda T., Okita S.et al. Infrequent somatic alteration of p16/MTS1 in human primary superficial bladder cancers. Cancer Letters. 103:1996;227-231.
49. Tamimi Y., Bringuier P.P., Smit F.et al. Homozygous deletions of p16(INK4) occur frequently in bilharziasis-associated bladder cancer. Int J Canc. 68:1996;183-187.
50. Kagan J., Liu K., Stein J.D.et al. Cluster of allele losses within a 2.5 cM region of chromosome 10 in high-grade invasive bladder cancer. Oncogene. 16:1998;909-913.
51. Cappellen D., Diez d Medina G., Chopin D.et al. Frequent loss of heterozygosity on chromosome 10q in muscle-invasive transitional cell carcinomas of the bladder. Oncogene. 14:1997;3059-3066.
52. Shaw M.E., Knowles M.A. Deletion mapping of chromosome 11 in carcinoma of the bladder. Genes Chromosomes Cancer. 13:1995;1-8.
53. Olumi A.F., Tsai Y.C., Nichols P.W.et al. Allelic loss of chromosome 17p distinguishes high grade from low grade transitional cell carcinomas of the bladder. Cancer Res. 50:1990;7081-7083.
54. Sauter G., Moch H., Wagner U.et al. Y chromosome loss detected by FISH in bladder cancer. Cancer Genet Cytogenet. 82:1995;163-169.
55. Ishikawa J., Xu H.-J., Hu S.-X.et al. Inactivation of the retinoblastoma gene in human bladder and renal cell carcinomas. Cancer Res. 51:1991;5736-5743.
56. Xu H.-J., Cairns P., Hu S.-X.et al. Loss of RB protein expression in primary bladder cancer correlates with loss of heterozygosity at the RB locus and tumor progression. Int J Cancer. 53:1993;781-784.
57. Serrano M., Hannon G.J., Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Letters to Nature. Nature. 366:1993;704-707.
58. Gonzalez-Zulueta M., Shibata A., Ohneseit P.F.et al. High frequency of chromosome 9p allelic loss and CDKN2 tumor suppressor gene alterations in squamous cell carcinoma of the bladder. J Natl Cancer Inst. 87:1995;1383-1392.
59. Spruck C.H. III, Rideout W.M. III, Olumi A.F.et al. Distinct pattern of p53 mutations in bladder cancer. relationship to tobacco usage Cancer Res. 53:1993;1162-1166.
60. Sidransky D., VonEschenbach A., Tsai Y.C.et al. Identification of p53 gene mutations in bladder cancers and urine samples. Science. 252:1991;706-709.
61. Panagopoulos I., Pandis N., Thelin S.et al. The FHIT and PTPRG genes are deleted in benign proliferative breast disease associated with familial breast cancer and cytogenetic rearrangements of chromosome band 3p14. Cancer Res. 56:1996;4871-4875.
62. Groden J., Thliveris A., Samowitz W.et al. Identification and characterization of the familial adenomatous polyposis coli gene. Cell. 66:1991;589-600.
63. Schreiber-Agus N., Meng Y., Hoang T.et al. Role of Mxi1 in aging organ systems and the regulation of normal and neoplastic growth. Letters to Nature. Nature. 393:1998;483-487.
64. Matsuoka S., Edwards M.C., Bai C.et al. p57KIP2, a structurally distinct member of the p21CIP1 cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev. 9:1995;650-662.
65. Hahn S.A., Schutte M., Hoque A.T.et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science. 271:1996;350-353.
66. Hinds P.W., Dowdy S.F., Eaton E.N.et al. Function of a human cyclin gene as an oncogene. Proc Natl Acad Sci. 91:1994;709-713.
67. Shin K.Y., Kong G., Kim W.S.et al. Overexpression of cyclin D1 correlates with early recurrence in superficial bladder cancers. Br J Cancer. 75:1997;1788-1792.
68. Wright C., Mellon K., Johnston P.et al. Expression of mutant p53, c-erbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder. Br J Cancer. 63:1991;967-970.
69. Tetu B., Fradet Y., Allard P.et al. Prevalence and clinical significance of HER-2/NEU, p53 and RB expression in primary superficial bladder cancer. J Urol. 155:1996;1784-1788.
70. Collins C., Rommens J.M., Kowbel D.et al. Positional cloning of ZNF217 and NABC1. Genes amplified at 20q13.2 and overexpressed in breast carcinoma Proc Natl Acad Sci. 95:1998;8703-8708.
71. Chow N.H., Liu H.S., Lee E.I.C.et al. Significance of urinary epidermal growth factor and its receptor expression in human bladder cancer. Anticancer Res. 17:1997;1293-1296.
72. Wang J., Xie L.Y., Allan S.et al. Myc activates telomerase. Genes Devel. 12:1998;1769-1774.
73. Reznikoff C.A., Yeager T.R., Belair C.D.et al. Elevated p16 at senescence and loss of p16 at immortalization in human papillomavirus 16 E6, but not E7, transformed human uroepithelial cells. Cancer Res. 56:1996;2886-2890.
74. Puthenveettil J.A., Burger M.S., Reznikoff C.A. Replicative senescence in human uroepithelial cells. J Urol. in press:1998.
75. Bartkova J., Lukas J., Guldberg P.et al. The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res. 56:1996;5475-5483.
76. Reznikoff C.A., Belair C., Savelieva E.et al. Long-term genome stability and minimal genotypic and phenotypic alterations in HPV16 E7-, but not E6-, immortalized human uroepithelial cells. Genes Dev. 8:1994;2227-2240.
77. Bruch J., Wöhr G., Hautmann R.et al. Chromosomal changes during progression of transitional cell carcinoma of the bladder and delineation of the amplified interval on chromosome arm 8q. Genes Chromosomes Cancer. 23:1998;167-178.
78. Vet J.A., Bringuier P.P., Schaafsma H.E.et al. Comparison of p53 protein overexpression with p53 mutation in bladder cancer. clinical and biologic aspects Lab Invest. 73:1995;837-843.
79. Lacombe L., Orlow I., Silver D.et al. Analysis of p21WAF1/CIP1 in primary bladder tumors. Oncol Res. 8:1996;409-414.
80. Stein J.P., Ginsberg D.A., Grossfeld G.D.et al. Effect of p21(WAF1/CIP1) expression on tumor progression in bladder cancer. J Natl Cancer Inst. 90:1998;1072-1079.
81. Haupt Y., Maya R., Kazaz A.et al. mdm2 promotes the rapid degradation of p53. Nature. 387:1997;296-298.
82. Xiao Z.-X., Chen J., Levine A.J.et al. Interaction between the retinoblastoma protein and the oncoprotein mdm2. Nature. 375:1995;694-698.
83. Sarkis A.S., Dalbagni G., Cordon-Cardo C.et al. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma. a marker for disease progression J Natl Cancer Inst. 85:1993;53-59.
84. Esrig D., Spruck C.H. III, Nichols P.W.et al. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade and stage in bladder cancer. Am J Pathol. 143:1993;1389-1397.
85. Esrig D., Elmajian D., Groshen S.et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med. 331:1994;1259-1264.
86. Tsutsumi M., Sugano K., Yamaguchi K.et al. Correlation of allelic loss of the p53 gene and tumor grade, stage, and malignant progression in bladder cancer. Inter J Urol. 41:1997;74-78.
87. Raitanen M.P., Tammela T.L., Kallioinen M.et al. p53 accumulation, deoxyribonucleic acid ploidy and progression of bladder cancer. J Urol. 157:1997;1250-1253.
88. Vet J.A., Witjes A.J., Marras S.A.E.et al. Predictive value of p53 mutations analyzed in bladder washings for progression of high-risk superficial bladder cancer. Clin Cancer Res. 2:1996;1055-1061.
89. Casetta G., Gontero P., Russo R.et al. p53 expression compared with other prognostic factors in OMS Grade-1 Stage-Ta transitional cell carcinoma of the bladder. Eur Urol. 32:1997;229-236.
90. Burkhard F.C., Markwalder R., Thalmann G.N.et al. Immunohistochemical determination of p53 overexpression. an easy and readily available method to identify progression in superficial bladder cancer? Urol Res. 25:1997;S31-S35.
91. Nakopoulou L., Constantinides C., Papandropoulos J.et al. Evaluation of overexpression of p53 tumor suppressor protein in superficial and invasive transitional cell bladder cancer. comparison with DNA ploidy Urol. 46:1995;334-340.
92. Vatne V., Maartmannmoe H., Hoestmark J. The prognostic value of p53 in superficially infiltrating transitional cell carcinoma. Scand J Urol Nephro. 29:1995;491-495.
93. Underwood M.A., Reeves J., Smith G.et al. Overexpression of p53 protein and its significance for recurrent progressive bladder tumours. Br J Urol. 77:1996;659-666.
94. Lipponen P.K., Liukkonen T.J. Reduced expression of retinoblastoma (Rb) gene protein is related to cell proliferation and prognosis in transitional-cell bladder cancer. J Cancer Res Clin Oncol. 121:1995;44-50.
95. Logothetis C.J., Xu H.-J., Ro J.Y.et al. Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer. J Natl Cancer Inst. 84:1992;1256-1261.
96. Grossman H.B., Liebert M., Antelo M.et al. p53 and RB expression predict progression in T1 bladder cancer. Clin Cancer Res. 4:1998;829-834.
97. Cordon-Cardo C., Zhang Z.-F., Dalbagni G.et al. Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors. Cancer Res. 57:1997;1217-1221.
98. Cote R.J., Dunn M.D., Chatterjee S.J.et al. Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res. 58:1998;1090-1094.
99. Imai T., Kimura M., Takeda M.et al. Significance of epidermal growth factor receptor and c-erbB-2 protein expression in transitional cell cancer of the upper urinary tract for tumour recurrence at the urinary bladder. Br J Cancer. 71:1995;69-72.
100. Sauter G., Moch H., Moore D.et al. Heterogeneity of erbB-2 gene amplification in bladder cancer. Cancer Res. 53:1993;2199-2203.
101. Wagner U., Sauter G., Moch H.et al. Patterns of p53, erbB-2, and EGF-r expression in premalignant lesions of the urinary bladder. Hum Pathol. 26:1995;970-978.
102. Neal D.E., Sharples L., Smith K.et al. The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer. 65:1990;1619-1625.
103. Underwood M., Bartlett J., Reeves J.et al. C-erbB-2 gene amplification. a molecular marker in recurrent bladder tumors? Cancer Res. 55:1995;2422-2430.
104. Moch H., Sauter G., Mihatsch J.et al. p53 but not erbB-2 expression is associated with rapid tumor proliferation in urinary bladder cancer. Hum Pathol. 25:1994;1346-1351.
105. Yeager T., Stadler W., Belair C.et al. Increased p16 levels correlate with pRb alterations in human urothelial cells. Cancer Res. 55:1995;493-497.
106. Bookland E.A., Reznikoff C.A., Lindstrom M.et al. Induction of thioguanine-resistant mutations in human uroepithelial cells by 4-aminobiphenyl and its N-hydroxy derivatives. Cancer Res. 52:1992;1615-1621.
107. Bookland E.A., Swaminathan S., Oyasu R.et al. Tumorigenic transformation and neoplastic progression of human uroepithelial cells after exposure in vitro to 4-aminobiphenyl or its metabolites. Cancer Res. 52:1992;1606-1614.
108. Christian B.J., Loretz L.J., Oberley T.D.et al. Characterization of human uroepithelial cells immortalized in vitro by simian virus 40. Cancer Res. 47:1987;6066-6073.
109. Kao C., Wu S.-Q., Bhatthacharya M.et al. Losses of 3p, 11p, and 13q in EJ/ras-transformable simian virus 40-immortalized human uroepithelial cells. Genes Chromosomes Cancer. 4:1992;158-168.
110. Belair C.D., Blelloch R.H., Reznikoff C.A. Immortalization of human uroepithelial cells by human papillomavirus 16 E6 or E7. Rad Onc Invest. 3:1996;368-376.
111. Savelieva E., Belair C.D., Newton M.A.et al. 20q gain associates with immortalization. 20q13.2 amplification correlates with genome instability in human papillomavirus 16 E7 transformed human uroepithelial cells Oncogene. 14:1997;551-560.
112. Puthenveettil J.A., Frederickson S.M., Reznikoff C.A. Apoptosis in human papillomavirus 16 E7-, but not E6-immortalized human uroepithelial cells. Oncogene. 13:1996;1123-1131.
113. Kamijo T., Zindy F., Roussel M.F.et al. Tumor suppression at the mouse er locus mediated by the alternative reading frame product p19ARF. Cell. 91:1997;649-659.
114. Pomerantz J., Schrieber-Agus N., Liégeois J.et al. The INK4a tumor suppressor gene product, p19ARF, interacts with MDM2 and neutralizes MDM2’s inhibition of p53. Cell. 92:1998;713-723.
115. Bates S., Phillips A.C., Clark P.A.et al. p14ARF links the tumour suppressors RB and p53. Science. 395:1998;124-125.
116. Palmero I., Pantoja C., Serrano M. p19ARF links the tumour suppressor p53 to RAS. Science. 395:1998;125-126.
117. Vieten L., Belair C.D., Savelieva L.et al. Minimal deletion of 3p13614.2 associated with immortalization of human uroepithelial cells. Genes Chromosomes Cancer. 21:1998;39-48.
118. Klingelhutz A.J., Wu S.-Q., Huang J.et al. Loss of 3p136p21.2 in tumorigenic reversion of a hybrid between isogeneic nontumorigenic and tumorigenic human uroepithelial cells. Cancer Res. 52:1992;1631-1634.
119. Klingelhutz A.J., Wu S.-Q., Bookland E.A.et al. Allelic 3p deletions in high-grade carcinomas after transformation in vitro of human uroepithelial cells. Genes Chromosomes Cancer. 3:1991;346-357.
120. Reznikoff C.A., Loretz L.J., Christian B.J.et al. Neoplastic transformation of SV40-immortalized human urinary tract epithelial cells by in vitro exposure to 3-methylcholanthrene. Carcinogenesis. 9:1988;1427-1436.
121. Pazzaglia S., Chen X.-R., Aamodt C.B.et al. In vitro radiation-induced neoplastic progression of low-grade uroepithelial tumors. Rad Research. 138:1994;86-92.
122. Christian B.J., Kao C., Wu S.-Q.et al. EJ/ras neoplastic transformation of simian virus 40-immortalized human uroepithelial cells. a rare event Cancer Res. 50:1990;4779-4780.
123. Pratt C.I., Kao C., Wu S.-Q.et al. Neoplastic progression by EJ/ras at different steps of transformation in vitro of human uroepithelial cells. Cancer Res. 52:1992;688-695.
124. Wu S.-Q., Storer B.E., Bookland E.A.et al. Nonrandom chromosome losses in stepwise neoplastic transformation in vitro of human uroepithelial cells. Cancer Res. 51:1991;3323-3326.
125. Newton M.A., Wu S.-Q., Reznikoff C.A. Addressing the significance of chromosome-loss data. where are suppressor genes for bladder cancer? Stat Med. 13:1994;839-858.
126. Kao C., Huang J., Wu S.-Q.et al. Role of SV40 T antigen binding to pRB and p53 in multistep transformation in vitro of human uroepithelial cells. Carcinogenesis. 14:1993;2297-2302.
127. Klingelhutz A.J., Wu S.-Q., Reznikoff C.A. Nonrandom chromosome losses in tumorigenic revertants of hybrids between isogenic immortal and neoplastic human uroepithelial cells. Somatic Cell Mol Genetics. 17:1991;551-565.
128. Pratt C.I., Wu S.-Q., Bhattacharya M.et al. Chromosome losses in tumorigenic revertants of EJ/ras-expressing somatic cell hybrids. Cancer Genet Cytogenet. 59:1992;180-190.
129. Belair C.D., Yeager T.R., Lopez P.M.et al. Telomerase activity. a biomarker of cell proliferation, not malignant transformation Proc Natl Acad Sci USA. 94:1997;13677-13682.
130. Kinoshita H., Ogawa O., Kakehi Y.et al. Detection of telomerase activity in exfoliated cells in urine from patients with bladder cancer. J Natl Cancer Inst. 89:1997;724-730.
131. Kavaler E., Landman J., Chang Y.et al. Detecting human bladder carcinoma cells in voided urine samples by assaying for the presence of telomerase activity. Cancer. 82:1998;708-714.